NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

Home・Akcijų sąrašas・Genmab A-S

Genmab A-S

Uždarymo kaina

1,621 0.06

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1606

Max

1628

Pagrindiniai rodikliai
By Trading Economics
Pajamos	21M 52M
Pardavimai	-184M 881M
P/E Sektoriaus vid.	18.691 49.052
Pelnas, tenkantis vienai akcijai	8.48
Pelno marža	5.915
Darbuotojai	3,088
EBITDA	-23M 221M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-1.49% downside

Dividendai
By Acuity
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-7.6B 97B
Ankstesnė atidarymo kaina	1620.94
Ankstesnė uždarymo kaina	1621

Genmab A-S Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-11 23:56; UTC

Event

Vertex Pharmaceuticals announced clinical benefits of CASGEVY® for severe sickle cell disease. Shares are trading lower in after-market hours, within a typical trading range.

2026-06-11 23:56; UTC

Correlated Moves

ETF Constituents

Macro News

iShares MSCI Brazil ETF trades higher after President Trump's cancellation of military strikes against Iran, boosting global investor confidence.

2026-06-11 23:56; UTC

News

Monster Beverage shares higher in after-market trading following Bernstein's initiation of coverage with a Market Perform rating. The stock has gained over four consecutive sessions.

2026-06-11 23:52; UTC

Michigan Consumer Sentiment Report for June 2026 Forecasts Continued Decline at 46.0 Amid Economic Pressures and Inflation Concerns

2026-06-11 23:52; UTC

Investors Await Key U.S. Building Permits Report Amid Cautious Market Sentiment Ahead of June 16 Release

2026-06-11 23:52; UTC

Macro Event

News

Correlated Moves

The Australian Dollar has gained against the Singapore Dollar, supported by a slight decline in consumer inflation expectations and recent geopolitical developments.

2026-06-11 23:51; UTC

News

The iShares Core U.S. Aggregate Bond ETF is trading lower in after-market hours, reflecting concerns over inflation following a rise in the producer price index.

2026-06-11 23:51; UTC

Correlated Moves

Lam Research Corp is rising in after-market trading, supported by a broader market rally and strong momentum near the upper end of its one-month trading range.

2026-06-11 23:51; UTC

Correlated Moves

Costco Wholesale Corp shares are higher in after-market hours, supported by a rising Nasdaq 100 Index and positive sentiment in the consumer staples sector.

2026-06-11 23:51; UTC

Trip.com Group Ltd is higher in after-market hours, reflecting broader market gains. No specific company news was identified to explain this movement.

2026-06-11 23:51; UTC

ETF Constituents

Vanguard FTSE Europe ETF is trading lower in after-market hours, impacted by declines from holdings including HSBC and Diageo, despite a generally higher market.

2026-06-11 23:51; UTC

Marriott International Inc. shares declined in after-market hours following Thursday's close, with no specific news identified to explain the movement.

2026-06-11 23:51; UTC

PepsiCo Inc shares are higher in after-market hours, driven by a significant overall market trend. The stock remains below its 20-day moving average.

2026-06-11 23:51; UTC

Lululemon Athletica is trading lower in after-market hours, reflecting a decline since Thursday's close. It reached a session low earlier in the session.

2026-06-11 23:51; UTC

Correlated Moves

ETF Constituents

News

Social Media

SPDR S&P 500 ETF Trust rises in after-hours trading amid improved market sentiment and reduced geopolitical tensions in Iran, supported by strong performances from top holdings.

2026-06-11 23:51; UTC

Correlated Moves

ETF Constituents

News

Social Media

Invesco QQQ Trust Series I rises after hours, supported by a Nasdaq 100 rally driven by technology stocks and easing inflation concerns.

2026-06-11 23:51; UTC

ETF Constituents

Correlated Moves

Macro News

Global X Copper Miners ETF declines in after-market trading as top holdings BHP and Southern Copper Corporation show slight decreases.

2026-06-11 23:51; UTC

Correlated Moves

Microchip Technology Inc is rising in after-market trading, reflecting broader market trends amid the European Central Bank's recent interest rate hike.

2026-06-11 23:51; UTC

Social Media

Correlated Moves

Micron Technology is trading higher in after-market hours, supported by positive market trends and favorable social media sentiment ahead of upcoming earnings.

2026-06-11 23:51; UTC

Correlated Moves

The Nasdaq 100 Index is higher today, continuing its upward trend. Initial jobless claims rose unexpectedly, but this has not impacted the index's momentum.

2026-06-11 23:51; UTC

News

The United States Oil Fund LP is higher in after-market trading amid reports of explosions in Iran raising concerns over oil supply stability.

2026-06-11 23:46; UTC

Intuitive Surgical Inc. shares are higher in after-market trading, advancing modestly since Thursday's close despite remaining below the 20-day moving average.

2026-06-11 23:46; UTC

Oil (Brent) is trading roughly flat with no specific news identified. It remains 7.63% below its 20-day moving average, indicating weak performance.

2026-06-11 23:46; UTC

ETF Constituents

Correlated Moves

The Vanguard FTSE Developed Markets ETF is trading higher in after-market hours, buoyed by the European Central Bank's interest rate hike and strong performances from SAP and BP.

2026-06-11 23:42; UTC

Housing Starts Data Release on June 16, 2026 Expected at 1.44 Million Amid Mixed Economic Sentiment and Inflation Concerns

2026-06-11 23:42; UTC

U.S. Import Prices Expected to Rise Amid Inflation Concerns and Geopolitical Tensions Ahead of June 16 Release

2026-06-11 23:42; UTC

U.S. Export Prices Expected to Rise 1% MoM Amid Mixed Economic Sentiment and Geopolitical Tensions Ahead of June 16 Release

2026-06-11 23:42; UTC

Market Awaits May Housing Starts Data Amid Economic Uncertainties and Rising Costs.

2026-06-11 23:42; UTC

U.S. Building Permits Expected to Rise Slightly to 1.41 Million Amid Cautious Optimism Ahead of June Release

2026-06-11 23:42; UTC

Macro News

ETF Constituents

Investor sentiment towards the Consumer Staples Select Sector SPDR Fund improves in after-market trading, buoyed by macro developments and strong performances from key holdings.

Akcijų palyginimas

Kainos pokytis

Genmab A-S Prognozė

Kainos tikslas

By TipRanks

-1.49% į apačią

12 mėnesių prognozė

Vidutinis 2,493.35 DKK -1.49%

Aukščiausias 3,320 DKK

Žemiausias 308.417 DKK

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Genmab A-S kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Genmab A-S akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.